Jounce Therapeutics to Present at the 2018 Cantor Global Healthcare Conference
September 26, 2018 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Second Quarter 2018 Financial Results
August 09, 2018 06:30 ET
|
Jounce Therapeutics, Inc.
- Initiated enrollment in dose escalation cohorts of Phase 1/2 ICONIC trial of JTX-2011, in combination with ipilimumab and in combination with pembrolizumab - - Presented preliminary efficacy data...
Jounce Therapeutics to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 9, 2018
August 02, 2018 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced Cancers
June 02, 2018 16:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., June 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting
May 16, 2018 17:01 ET
|
Jounce Therapeutics, Inc.
ICONIC Target Enrollment Met Across Four Combination Cohorts Company to Host Investor Event and Live Webcast on Monday, June 4 CAMBRIDGE, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- Jounce...
Jounce Therapeutics Reports First Quarter 2018 Financial Results
May 09, 2018 06:30 ET
|
Jounce Therapeutics, Inc.
- Preliminary efficacy data from Phase 1/2 ICONIC trial to be presented as an oral presentation at the 2018 ASCO Annual Meeting - - Company to host conference call and webcast today at 8:00 AM ET - ...
Jounce Therapeutics to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018
May 02, 2018 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., May 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present at Deutsche Bank 43rd Annual Health Care Conference
May 01, 2018 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present Nonclinical Translational Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting
April 12, 2018 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 12, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
March 08, 2018 06:30 ET
|
Jounce Therapeutics, Inc.
- Remain on track to announce preliminary efficacy data for the Phase 1/2 ICONIC trial in the second quarter of 2018 - - Reiterate 2018 strategy to advance clinical and research pipeline to drive...